InspireMD, Inc. NSPR
0.80 USD +0.02 (+2.42%)
At closeNov 11, 2026, 4:00 PM EST
0.80 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
0.7301 Day range 0.82
0.43 52-week range 2.22
- YTD
- -55.06%
- 1 year
- -50.92%
News
globenewswire.com InspireMD Announces Updated Timing for Third Quarter 2026 Financial Results MIAMI, Nov. 11, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it has rescheduled its…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares rose 211.2% to $1.88 during Monday's regular session. The company's market cap stands at $62.2 million. BeyondSpring (NASDAQ:BYSI) stock moved…
globenewswire.com InspireMD to Announce Third Quarter 2026 Financial Results MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares increased by 27.9% to $2.79 during Friday's pre-market session. The company's market cap stands at $5.2 million. Picard Medical (AMEX:PMI) stock…
globenewswire.com InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million - Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to anticipate in Q4 2026 -- benzinga.com Full Transcript: InspireMD Q2 2026 Earnings Call InspireMD (NASDAQ:NSPR) reported second-quarter financial results on Monday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you…
globenewswire.com InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, Sept. 04, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today…
globenewswire.com InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Can Fite Biopharma (AMEX:CANF) shares moved upwards by 20.4% to $3.96 during Wednesday's pre-market session. The company's market cap stands at $7.0 million. Aligos Therapeutics (NASDAQ:ALGS)…
benzinga.com Why Dell Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket Dell Technologies (DELL) stock jumps in pre-market trading after reporting better-than-expected Q2 results and raising FY27 guidance. Other gainers include UPC, GTLB, VIVK, UFG, MLEC, FFAI, GPUS,…
zacks.com InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know InspireMD (NSPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
seekingalpha.com InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript
benzinga.com InspireMD Q2 EPS $(0.17) Beats $(0.19) Estimate, Sales $1.771M Miss $2.133M Estimate InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 34.62 percent increase over losses of $(0.26)…
globenewswire.com InspireMD Reports Second Quarter 2026 Financial Results - Company to host investor conference call today, August 17 th , at 8:30am EDT - MIAMI, Aug. 17, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of…
zacks.com InspireMD, Inc. (NSPR) Reports Q2 Loss, Beats Revenue Estimates InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.26 per share a year ago.
globenewswire.com InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today…
globenewswire.com InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing Ms. Kennedy returns to InspireMD having previously served as Sales Director supporting the initial U.S. launch of CGuard Prime Ms. Kennedy returns to InspireMD having previously served as Sales…
zacks.com InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR NSPR's positive CGUARDIANS II data show 100% acute device success, supporting a potential FDA approval for CGuard Prime TCAR in late 2026.
globenewswire.com InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, June 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today…
benzinga.com InspireMD Announces 30-Day Outcomes From CGUARDIANS II Clinical Trial Of CGuard Prime 80cm Implant For Use In Transcarotid Artery Revascularization Procedures InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced 30-day outcomes from the CGUARDIANS II…
globenewswire.com InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures MIAMI, June 11, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today…- benzinga.com InspireMD Announces First Patient Enrolled In CGUARDIANS III Pivotal Study Of SwitchGuard Neuro Protection System, For Use With CGuard Prime 80 cm Stent Platform, In TCAR Procedures InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the first patient has been…
globenewswire.com InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures MIAMI, June 08, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today…
seekingalpha.com InspireMD, Inc. (NSPR) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript InspireMD, Inc. (NSPR) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
globenewswire.com InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference MIAMI, May 06, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today…
benzinga.com Piper Sandler Reiterates Overweight on InspireMD, Lowers Price Target to $3 Piper Sandler analyst Adam Maeder reiterates InspireMD (NASDAQ:NSPR) with a Overweight and lowers the price target from $4 to $3.
zacks.com InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.22 per share a year ago.
seekingalpha.com InspireMD, Inc. (NSPR) Q1 2026 Earnings Call Transcript InspireMD, Inc. (NSPR) Q1 2026 Earnings Call Transcript- benzinga.com Transcript: InspireMD Q1 2026 Earnings Conference Call
benzinga.com InspireMD Q1 EPS $(0.16) Beats $(0.19) Estimate, Sales $3.398M Beat $2.698M Estimate InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.19) by 15.79 percent. This is a 27.27 percent increase over losses of $(0.22)…
globenewswire.com InspireMD Reports First Quarter 2026 Financial Results - Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% - - Received IDE approval from FDA to initiate the CGUARDIANS III clinical trial of its SwitchGuard neuro…
benzinga.com Earnings Scheduled For May 4, 2026 
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com InspireMD Withdraws Prior Full Year 2026 Revenue Guidance; Says Given The Impact Of The Temporary Discontinuation Of Commercial Activity In The U.S. Pending The Anticipated FDA Approval Of Its Original CGuard Stent Delivery System In Q3 2026 2026 Financial GuidanceConcurrent with today's announcement, the Company is withdrawing its prior full year 2026 revenue guidance. Management believes this is the most prudent step given the impact…
- benzinga.com InspireMD Initiates Voluntary U.S. Recall Of CGuard Prime 135cm Carotid Stent Delivery System; Recall Follows Technical Performance Of CGuard Prime 135cm Not Meeting Expectations; Recall Does Not Include CGuard Stent Implant; FDA Approval Of CGuard Prime 80cm For TCAR Anticipated In 2H 2026; FDA Approval, U.S. Availability Of Original CGuard Delivery System Anticipated In Q3 2026; Implementing Design Improvements To CGuard Prime Stent Delivery System - Strong clinical demand continues in Q1 2026 with global year-over-year unit sales growth of 53% and quarter-over-quarter U.S. unit sales growth of 34% - - FDA approval anticipated with U.S. market…
- benzinga.com InspireMD Initiates Voluntary Recall For Its CGuard Prime 135 Cm Carotid Stent Delivery System InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD," or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that, in consultation with the U.S.…
- benzinga.com InspireMD Says FDA Approves IDE Application To Initiate CGUARDIANS III Pivotal Study Of SwitchGuard NPS, Including Next Gen Enhancements From Prior IDE Approval For Use With CGuard Prime 80 cm Stent Platform, In TCAR Procedures InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the U.S. Food and Drug…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Earnings Scheduled For March 18, 2026
- benzinga.com InspireMD Q4 EPS $(0.14) Beats $(0.19) Estimate, Sales $3.149M Beat $2.626M Estimate InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.19) by 27.46 percent. This is a 26.32 percent increase over losses of $(0.19)…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com InspireMD Publishes Data From Its C-GUARDIANS Pivotal Study Journal Of The American College of Cardiology InspireMD, Inc. (Nasdaq: NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that results from the Company's…
benzinga.com InspireMD CREST-2 Data Demonstrates Addition Of Stenting Improves Outcomes In Trial For Participants With Asymptomatic Carotid Stenosis InspireMD, Inc. (Nasdaq: NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, welcomes the recent presentation and publication of…
benzinga.com Earnings Scheduled For November 4, 2025 
benzinga.com Earnings Scheduled For August 5, 2025 - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Why BlackBerry Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket